Indiana § 12-23-18-7 Adoption of rules establishing standards and protocols; use of
alternative medication for treatment; explanation of side effects

Indiana Statutes

§ 12-23-18-7 — Adoption of rules establishing standards and protocols; use of alternative medication for treatment; explanation of side effects

Indiana § 12-23-18-7

Art. 23ADDICTION SERVICES

Ch. 18Opioid Treatment Diversion Control and Oversight

This text of Indiana § 12-23-18-7 (Adoption of rules establishing standards and protocols; use of alternative medication for treatment; explanation of side effects) is published on Counsel Stack Legal Research, covering Indiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Ind. Code § 12-23-18-7 (2026).

Text

(a)The division shall adopt rules under IC 4-22-2 to establish standards and protocols for opioid treatment programs to do the following:

(1)Assess new opioid treatment program patients to determine the most effective opioid treatment medications to start the patient's opioid treatment.

(2)Ensure that each patient voluntarily chooses maintenance treatment and that relevant facts concerning the use of opioid treatment medications are clearly and adequately explained to the patient.

(3)Have appropriate opioid treatment program patients who are receiving methadone for opioid treatment move to receiving other approved opioid treatment medications.

(b)An opioid treatment program shall follow the standards and protocols adopted under subsection (a) for each opioid treatment program patient.

Free access — add to your briefcase to read the full text and ask questions with AI

(a) The division shall adopt rules under IC 4-22-2 to establish standards and protocols for opioid treatment
programs to do the following:
(1) Assess new opioid treatment program patients to determine
the most effective opioid treatment medications to start the
patient's opioid treatment.
(2) Ensure that each patient voluntarily chooses maintenance
treatment and that relevant facts concerning the use of opioid
treatment medications are clearly and adequately explained to the
patient.
(3) Have appropriate opioid treatment program patients who are
receiving methadone for opioid treatment move to receiving other
approved opioid treatment medications.
(b) An opioid treatment program shall follow the standards and
protocols adopted under subsection (a) for each opioid treatment
program patient.
(c) Subject to subsection (a), an opioid treatment program may use
any of the following medications as an alternative for methadone for
opioid treatment:
(1) Buprenorphine.
(2) Buprenorphine combination products containing naloxone.
(3) Naltrexone injectable and extended release.
(4) A federal Food and Drug Administration approved long
acting, nonaddictive medication for the treatment of opioid or
alcohol dependence.
(5) Any other medication that has been approved by:
(A) the federal Food and Drug Administration for use in the
treatment of opioid addiction; and
(B) the division under subsection (e).
(d) Before starting a patient on a new opioid treatment medication,
the opioid treatment program shall explain to the patient the potential
side effects of the new medication.
(e) The division may adopt rules under IC 4-22-2 to provide for
other medications, including a federal Food and Drug Administration
approved long acting, nonaddictive medication for the treatment of
opioid or alcohol dependence, as alternatives to methadone that may be
used under subsection (a).